XL 019

Drug Profile

XL 019

Alternative Names: XL019

Latest Information Update: 26 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Myelofibrosis; Polycythaemia vera

Most Recent Events

  • 04 Apr 2011 Discontinued - Phase-I for Myelofibrosis in USA (PO)
  • 04 Apr 2011 Discontinued - Phase-I for Polycythaemia vera in USA (PO)
  • 08 Dec 2008 Interim efficacy & adverse events data from a phase I trial in patients with advanced myelofibrosis presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top